Sage Therapeutics (SAGE) Shares are Down -1.05%

Sage Therapeutics (SAGE) has risen sharply, recording gains of 26.27% in the past 4 weeks. However, the stock has corrected -1.05% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 26.95% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 7.03% and the 50-Day Moving Average is 11.55%.The 200 Day SMA reached 22.05%


Sage Therapeutics (NASDAQ:SAGE): After opening at $45.87, the stock dipped to an intraday low of $45.36 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $47 and the buying power remained strong till the end. The stock closed at $46.05 for the day, a gain of 1.14% for the day session. The total traded volume was 746,785. The stocks close on the previous trading day was $46.05.

Sage Therapeutics (SAGE) : 6 investment research analysts covering Sage Therapeutics (SAGE) have an average price target of $69 for the near short term. The highest target price given by the Brokerage Firm to the stock is $95 and the lowest target is $18 for the short term. Analysts expect the variance to be within $28.96 of the average price.

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Companys lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.